OKYO Pharma Limited logo

OKYO Pharma (OKYO) stock

OKYO · OKYO Pharma Limited · NASDAQ

Website
Market cap
$60.9M
Shares out
52.5M

What is the latest news on OKYO stock?

SECago
SEC Form 6-K filed by OKYO Pharma Limited

6-K - OKYO Pharma Ltd (0001849296) (Filer)

All OKYO news

When does OKYO Pharma report earnings?

The latest OKYO Pharma earnings release came out on Nov 15, 2024: MUSQ Global Music Industry ETF and OKYO Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV. Before that, OKYO Pharma reported on Aug 23, 2024 and Jan 31, 2024.

OKYO earnings history

Financial highlights

Full financials
Revenue, FY2026
$32.1K
Revenue growth
+486.5%
Net income, FY2026
-$8.95M
Net margin
-27882.3%
Free cash flow, FY2026
-$5.94M
Cash
$14.59M

For fiscal 2026 (ended Mar 31, 2026), from SEC filings. Not investment advice.

Latest news

25 items

OKYO rankings

News · 26 weeks610%
2026-05-24: 02026-05-31: 32026-06-07: 52026-06-14: 12026-06-21: 02026-06-28: 02026-07-05: 42026-07-12: 02026-07-19: 222026-07-26: 62026-08-02: 82026-08-09: 02026-08-16: 02026-08-23: 02026-08-30: 02026-09-06: 42026-09-13: 02026-09-20: 02026-09-27: 22026-10-04: 22026-10-11: 02026-10-18: 02026-10-25: 02026-11-01: 22026-11-08: 22026-11-15: 0
2026-05-242026-11-15
Mix1290d
  • Other6(50%)
  • SEC Filings6(50%)
Activity · 52 weeks11846 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news

OKYO Pharma Limited (OKYO) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. In the last 30 days Quantisnow tracked 4 wire items for OKYO, including 2 press releases and news items and 2 SEC filings. The most recent was published Nov 12, 2026.

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. It is developing OK-101 for the treatment of dry eye disease; and OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. The company is also developing chemerin and chemerin analogues to treat the cytokine release syndrome associated with COVID-19 infections and other conditions, such as acute respiratory distress syndrome. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

OKYO FAQ

10 questions
  • What does OKYO Pharma Limited do?
    OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. It is developing OK-101 for the treatment of dry eye disease; and OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. The company is also developing chemerin and chemerin analogues to treat the cytokine release syndrome associated with COVID-19 infections and other conditions, such as acute respiratory distress syndrome. OKYO...
  • What is OKYO revenue?
    OKYO Pharma Limited (OKYO) reported $32.1K of revenue for fiscal 2026 (ended Mar 31, 2026). That is up 486.5% from the year before.
  • Is OKYO profitable?
    No. OKYO Pharma Limited reported a net loss of $8.95M for fiscal 2026 (ended Mar 31, 2026).
  • How much cash and debt does OKYO have?
    OKYO Pharma Limited reported $14.59M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • Where does OKYO stock trade?
    OKYO Pharma Limited (OKYO) is listed on NASDAQ.
  • What sector and industry is OKYO in?
    OKYO Pharma Limited operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.
  • When did OKYO Pharma Limited go public?
    OKYO Pharma Limited (OKYO) completed its IPO in 2022.
  • What are analysts saying about OKYO?
    OKYO Pharma Limited has had 2 recent analyst actions on file. The most recent action was from Piper Sandler: Overweight with a $7.00 price target on 2026-02-20. Recent price targets range from $5.00 to $7.00.
  • What companies are similar to OKYO?
    Notable peers in the same industry include EXEL (Exelixis Inc.), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.), MRNA (Moderna Inc.), GILD (Gilead Sciences Inc.). Compare OKYO side-by-side with any of them on Quantisnow.
  • How can I track OKYO on Quantisnow?
    Quantisnow aggregates OKYO Pharma Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow OKYO to receive live email and push alerts on every new disclosure.

Is something on this page wrong, or out of date? Request a change